Long Term Treatment Concepts and Proactive Therapy for Atopic Eczema
3
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Atopic eczema, also known as atopic dermatitis, is a frequent, highly pruritic, chronic skin disease, which is typically running in flares. The traditional treatment mainly consists of the reactive application of topical anti-inflammatory agents such as topical corticosteroids and topical calcineurin inhibitors. The short term benefit of this approach is well known, but long term remission between flares is difficult to achieve. Therefore, innovative long-term treatment strategies targeting flare prevention and skin barrier stabilization are needed. We and others have shown that normal looking,non-lesional skin of atopic dermatitis patients is immunobiologially not normal but characterized by an invisible inflammation and barrier defect. This has led to the novel concept of proactive therapy, which is defined as long-term,low-dose intermittent application of anti-inflammatory therapy to the previously affected skin, together with an ongoing emollient treatment of unaffected skin. This review article describes the most important long-term treatment options for atopic dermatitis, which includes emollient therapy, the novel concept of proactive treatment, the different ultraviolet light modalities and a selection of systemic immunosuppressive drugs and biologics. Current trial data, licensed indications, off-label use and relevant side effects of the different treatment modalities are summarized.
Abstract
Atopic eczema, also known as atopic dermatitis, is a frequent, highly pruritic, chronic skin disease, which is typically running in flares. The traditional treatment mainly consists of the reactive application of topical anti-inflammatory agents such as topical corticosteroids and topical calcineurin inhibitors. The short term benefit of this approach is well known, but long term remission between flares is difficult to achieve. Therefore, innovative long-term treatment strategies targeting flare prevention and skin barrier stabilization are needed. We and others have shown that normal looking,non-lesional skin of atopic dermatitis patients is immunobiologially not normal but characterized by an invisible inflammation and barrier defect. This has led to the novel concept of proactive therapy, which is defined as long-term,low-dose intermittent application of anti-inflammatory therapy to the previously affected skin, together with an ongoing emollient treatment of unaffected skin. This review article describes the most important long-term treatment options for atopic dermatitis, which includes emollient therapy, the novel concept of proactive treatment, the different ultraviolet light modalities and a selection of systemic immunosuppressive drugs and biologics. Current trial data, licensed indications, off-label use and relevant side effects of the different treatment modalities are summarized.
참고문헌 (61)
- Darsow U, "ETFAD", EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis, 2010, pp.24, 317~328
- Ring J, "Guidelines for Treatment of Atopic Eczema (Atopic Dermatitis)", J Eur Acad Dermatol Venereol (2011)
- Ring J, "Dermatitis, In Braun-Falco's Dermatology" (2008), Springer
- Darsow U, "Position paper on diagnosis and treatment of atopic dermatitis", J Eur Acad Dermatol Venereol, 19, pp.286~295 (2005)
- Reitamo S, "Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis", Allergy Clin Immunol, 109, pp.547~555 (2002)
- Reitamo S, "Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group", Arch Dermatol, 136, pp.999~1006 (2000)
- Ogawa H, "Atopic dermatitis: studies of skin permeability and effectiveness of topical PUVA treatment", Pediatr Dermatol, 9, pp.383~385 (1992)
- Proksch E, "Skin barrier function, epidermal proliferation and differentiation in eczema", J Dermatol Sci, 43, pp.159~169 (2006)
- Werner Y, "Transepidermal water loss in dry and clinically normal skin in patients with atopic dermatitis", Acta Derm Venereol, 65, pp.102~105 (1985)
- Wollenberg A, "Proactive therapy of atopic eczema--an evidence-based concept with a behavioral background", J Dtsch Dermatol Ges, 7, pp.117~121 (2009)
- Weidinger S, "Filaggrin mutations, atopic eczema, hay fever, and asthma in children", J Allergy Clin Immunol, 121, pp.1203~1209 (2008)
- Macheleidt O, "Deficiency of epidermal protein-bound omega-hydroxyceramides in atopic dermatitis", J Invest Dermatol, 119, pp.166~173 (2002)
- Mihm MC Jr, "The structure of normal skin and the morphology of atopic eczema", J Invest Dermatol, 67, pp.305~312 (1976)
- Wollenberg A, "Innate immunity in atopic dermatitis", Clin Rev Allergy Immunol, 41, pp.272~281 (2011)
- Wollenberg A, "Phenotyping of epidermal dendritic cells: clinical applications of a flow cytometric micromethod", Cytometry, 37, pp.147~155 (1999)
- Wollenberg A, "Proactive therapy of atopic dermatitis--an emerging concept", Allergy, 64, pp.276~278 (2009)
- Van Der Meer JB, "The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands Adult Atopic Dermatitis Study Group", Br J Dermatol, 140, pp.1114~1121 (1999)
- Wollenberg A, "Proaktive und reaktive Behandlungsansätze der Neurodermitis mit differenten Externa", J Dtsch Dermatol Ges, 5(Suppl 2), pp.105~ (2007)
- Frankl VE, "Der Mensch auf der Suche nach Sinn" (1972), Ernst Klett Verlag
- Hanifin J, "Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients", Br J Dermatol, 147, pp.528~537 (2002)
- Berth-Jones J, "Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study", BMJ, 326, pp.1367~ (2003)
- Glazenburg EJ, "Efficacy and safety of fluticasone propionate 0.005% ointment in the long-term maintenance treatment of children with atopic dermatitis: differences between boys and girls?", Pediatr Allergy Immunol, 20, pp.59~66 (2009)
- Peserico A, "Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study", Br J Dermatol, 158, pp.801~807 (2008)
- Wollenberg A, "Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment", Allergy, 63, pp.742~750 (2008)
- Thaçi D, "Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study", Br J Dermatol, 159, pp.1348~1356 (2008)
- Reitamo S, "Treatment with twice-weekly tacrolimus ointment in patients with moderate to severe atopic dermatitis: results from two randomized, multicentre, comparative studies", J Dermatolog Treat, 21, pp.34~44 (2010)
- Paller AS, "Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use", Pediatrics, 122, pp.e1210~e1218 (2008)
- Breneman D, "Intermittent therapy for flare prevention and longterm disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle", J Am Acad Dermatol, 58, pp.990~999 (2008)
- Wollenberg A, "Economic evaluation of maintenance treatment with tacrolimus 0.1% ointment in adults with moderate to severe atopic dermatitis", Br J Dermatol, 159, pp.1322~1330 (2008)
- Aly R, "Microbial flora of atopic dermatitis", Arch Dermatol, 113, pp.780~782 (1977)
- Wollenberg A, "Evolution of conventional therapy in atopic dermatitis", Immunol Allergy Clin North Am, 30, pp.351~368 (2010)
- Gauger A, "Efficacy and functionality of silver-coated textiles in patients with atopic eczema", J Eur Acad Dermatol Venereol, 20, pp.534~541 (2006)
- Koller DY, "Action of a silk fabric treated with AEGIS in children with atopic dermatitis: a 3-month trial", Pediatr Allergy Immunol, 18, pp.335~338 (2007)
- Stinco G, "A randomized double-blind study to investigate the clinical efficacy of adding a non-migrating antimicrobial to a special silk fabric in the treatment of atopic dermatitis", Dermatology, 217, pp.191~195 (2008)
- Huang JT, "Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity", Pediatrics, 123, pp.e808~e814 (2009)
- Gauger A, "Silver-coated textiles reduce Staphylococcus aureus colonization in patients with atopic eczema", Dermatology, 207, pp.15~21 (2003)
- Dotterud LK, "The effect of UVB radiation on skin microbiota in patients with atopic dermatitis and healthy controls", Int J Circumpolar Health, 67, pp.254~260 (2008)
- Griffiths CE, "Update on the use of ciclosporin in immune-mediated dermatoses", Br J Dermatol, 155(Suppl 2), pp.1~16 (2006)
- Hijnen DJ, "Efficacy and safety of long-term treatment with cyclosporin A for atopic dermatitis", J Eur Acad Dermatol Venereol, 21, pp.85~89 (2007)
- Berth-Jones J, "Cyclosporine in severe childhood atopic dermatitis: a multicenter study", J Am Acad Dermatol, 34, pp.1016~1021 (1996)
- Norgauer J, "Systemische Therapie der Psoriasis und des atopischen Ekzems", Thieme Praxis Report, 3 (2011)
- Schmitt J, "Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials", Br J Dermatol, 164, pp.415~428 (2011)
- Thomas Bieber, "Atopic Dermatitis", Annals of Dermatology, 22(2), pp.125~137 (2010), 대한피부과학회
- Liu HN, "In vitro immunosuppressive effects of methotrexate and azathioprine on Langerhans cells", Arch Dermatol Res, 289, pp.94~97 (1997)
- Hon KL, "Efficacy and tolerability at 3 and 6 months following use of azathioprine for recalcitrant atopic dermatitis in children and young adults", J Dermatolog Treat, 20, pp.141~145 (2009)
- Grundmann-Kollmann M, "Mycophenolate mofetil is effective in the treatment of atopic dermatitis", Arch Dermatol, 137, pp.870~873 (2001)
- Benez A, "Successful long-term treatment of severe atopic dermatitis with mycophenolate mofetil", Br J Dermatol, 144, pp.638~639 (2001)
- Grundmann-Kollmann M, "Successful treatment of severe refractory atopic dermatitis with mycophenolate mofetil", Br J Dermatol, 141, pp.175~176 (1999)
- Bangert CA, "Methotrexate in dermatology", Dermatol Ther, 20, pp.216~228 (2007)
- Schram ME, "A randomized trial of methotrexate versus azathioprine for severe atopic eczema", J Allergy Clin Immunol, 128, pp.353~359 (2011)
- Goujon C, "Methotrexate for the treatment of adult atopic dermatitis", Eur J Dermatol, 16, pp.155~158 (2006)
- Weatherhead SC, "An open-label, dose-ranging study of methotrexate for moderateto-severe adult atopic eczema", Br J Dermatol, 156, pp.346~351 (2007)
- Buka RL, "Etanercept is minimally effective in 2 children with atopic dermatitis", J Am Acad Dermatol, 53, pp.358~359 (2005)
- Jacobi A, "Infliximab in the treatment of moderate to severe atopic dermatitis", J Am Acad Dermatol, 52, pp.522~526 (2005)
- Oldhoff JM, "Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis", Allergy, 60, pp.693~696 (2005)
- Forman SB, "Success of omalizumab as monotherapy in adult atopic dermatitis: case report and discussion of the high-affinity immunoglobulin E receptor, FcepsilonRI", Cutis, 80, pp.38~40 (2007)
- Lane JE, "Treatment of recalcitrant atopic dermatitis with omalizumab", J Am Acad Dermatol, 54, pp.68~72 (2006)
- Simon D, "Anti-CD20 (rituximab) treatment improves atopic eczema", J Allergy Clin Immunol, 121, pp.122~128 (2008)
- Werfel T, "Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study", Allergy, 61, pp.202~205 (2006)
- Kupfer J, "Structured education program improves the coping with atopic dermatitis in children and their parents-a multicenter, randomized controlled trial", J Psychosom Res, 68, pp.353~358 (2010)
- Grahovac M, "Treatment of atopic eczema with oral alitretinoin", Br J Dermatol, 162, pp.217~218 (2010)